abstract: Sixty @entity1 with @entity0 (mean age: 61 years; range 36-78 years) were treated with @entity1259 ( @entity1259 ), 60 mg m-2, as single drug therapy. The drug was administered as 2 hours' constant rate infusions. The pharmacokinetics of the drug during the first course of treatment was evaluated by measurements of the plasma concentration of @entity1259 at the end of the infusion period. There was a five-fold inter-individual variation of the dose-normalized maximum plasma concentration, which increased with increasing age of the @entity1 . There was no correlation between this pharmacokinetic parameter and degree of @entity28 . An increase in maximum plasma concentration was associated with an increasing degree of @entity1665 (p = 0.025). Also the degree of @entity390 and @entity391 showed a tendency to increase with increasing maximum plasma concentration (p = 0.07). Fifty four of the sixty @entity1 entered in the present study were evaluable for clinical response. There was one CR (complete remission). Seventeen @entity1 achieved PR (partial response), and twenty five @entity1 had @entity66 ( @entity66 ). Eleven @entity1 did not respond to treatment. The median maximum plasma concentrations were 322, 316, 336 and 288 ng ml-1 in @entity1 with CR, PR, @entity66 and @entity1726 , respectively. The results in the present study showed that 60 mg m-2 of @entity1259 given as a constant rate infusion over 2 hours is a useful alternative to more @entity146 combination drug therapy for the treatment of @entity0 .

title: XXXX as a single agent therapy for the treatment of @entity0 --a pharmacokinetic and clinical study.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['stable disease', 'SD']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['aggressive']

entities_list: @entity1259 :: ('MESH:D015251', 'Chemical') :: ["4'epi-Doxorubicin", 'Epirubicin']

entities_list: @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting']

answer: @entity1259 :: (MESH:D015251,Chemical) :: ['Epirubicin']


abstract: OBJECTIVE: To evaluate the value of T2WI, DWI and 3D-VBIE at 3.0 T MR in the differentiation of recurrent @entity5 and benign pelvic lesions after curative rectal operation. METHODS: A total of 28 @entity1 with abnormal pelvic lesions confirmed by CT or MR from April 2007 to October 2010 were evaluated with MR imaging. All the @entity1 received examinations of both T2WI and DWI, and 24 of them received additional examination of 3D-VIBE. Thirteen @entity1 with MR imaging in the same period who were confirmed to have no diseases of the rectum were used as control group. The mean apparent diffusion coefficient(ADC) value and the ratio of the signal intensity(SI) of the lesions to the gluteus maximus in T2WI(SI(L)/SI(M)) and the ratio of the net added signal intensity of the lesions to the net added signal intensity of the iliac artery(SI(L)/SI(A)) at the time of 35 seconds after the iliac artery achieved its highest intensity were measured and calculated. The type of the time-intensity curve(TIC) was over viewed and classified as the benign type when the TIC was rising slowly or constantly and lasted for more than 90 s; however the malignant type when the TIC was rising significantly but lasted less than 90 s kept as a horizontal line for a period or was descending slowly or rising slowly. RESULTS: There were 29 lesions of different final diagnosis, including 17 recurrence @entity5 , 4 fibrous masses, 6 stoma @entity32 , 1 sinus and 1 abscess. Fourteen of them were confirmed by pathological examination. The ratio of SI(L)/SI(M) was 2.84  1.52 in the benign group, 2.58  0.80 in the malignant group, and 2.13  0.58 in the control group, the differences between the 3 groups were not statistically significant(F=1.620, P=0.211). When the ADC value of 1.21 10(-3) mm(2)/s was set as a diagnostic threshold, the sensitivity, specificity, accuracy and coherence for the diagnosis of the malignant lesions were 100%(17/17), 91.7%(11/12), 96.6%(28/29) and 0.928, respectively. When the SI(L)/SI(A) value of 0.28 was set as a diagnostic threshold, the sensitivity, specificity, accuracy and coherence for the diagnosis of the malignant lesions were 100%(13/13), 66.7%(8/12), 84.0%(21/25) and 0.675. When considering the TIC as the diagnostic standard, the sensitivity, specificity and accuracy for the diagnosis of the malignant lesions were 100%(13/13), 83.3%(10/12) and 92.0%(23/25), respectively. CONCLUSION: The signal intensity of T2WI has no specificity in the differentiation of malignant lesions and benign lesions while the DWI and the 3D-VIBE have high values in it.

title: [Differentiation of recurrence XXXX and benign pelvic lesions after curative rectal operation with 3.0 T magnetic resonance].

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['rectal cancers', 'rectal cancer']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammations']

answer: @entity5 :: (MESH:D009369,Disease) :: ['rectal cancer']


abstract: Hepatic neutrophil adhesion during @entity5694 is an integrin-independent, @entity3844 -dependent process. Because integrins function in other endotoxemic vasculatures, we used spinning disk confocal intravital microscopy to assess whether @entity558 down-modulated integrin functions in sinusoids. First, we applied fMLP onto the liver surface, and compared it with systemic @entity558 administration. Local fMLP caused neutrophil adhesion, crawling, and emigration for at least 2 h. Surprisingly, the number of adherent and crawling neutrophils was markedly reduced in @entity3804 (-/-) and @entity8024 (-/-) @entity19 , but not in @entity19 treated with anti- @entity3844 mAb. By contrast, systemic @entity558 injection induced a robust accumulation of neutrophils in sinusoids, which was dependent on @entity3844 , but not on integrins. Strikingly, local fMLP could not induce any integrin-dependent adhesion in endotoxemic @entity19 treated with anti- @entity3844 mAb, indicating that @entity3804 -dependent neutrophil adhesion was inhibited by @entity558 . This response was localized to the hepatic microvasculature because neutrophils still adhered via integrins in brain microvasculature. @entity8024 / @entity31454 levels were not decreased, but following @entity558 treatment, @entity3804 was down-regulated in neutrophils localized to liver, but not in the circulation. @entity3804 down-regulation in neutrophils was not observed in @entity1618 (-/-) @entity19 . In vitro neutrophil incubation with @entity1618 induced direct decrease of @entity3804 expression and adhesivity in @entity558 -stimulated neutrophils. Therefore, our data suggest that @entity3804 is necessary for neutrophil adhesion and crawling during local inflammatory stimuli in sinusoids, but during systemic @entity32 , neutrophils are exposed to high concentrations of @entity1618 , leading to a @entity3844 -dependent, integrin-independent adhesion. This may be a mechanism to keep neutrophils in sinusoids for intravascular trapping.

title: Selective down-regulation of neutrophil @entity3804 in endotoxemic hepatic microcirculation via XXXX .

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity5694 :: ('MESH:D019446', 'Disease') :: ['endotoxemia']

answer: @entity1618 :: (16153(Tax:10090),Gene) :: ['IL-10']


abstract: Elderly @entity1 have an increased risk to suffer from @entity1282 due to age-related physiological alterations and @entity16 . The consequences of untreated @entity1282 are @entity3147 and @entity2700 and the aspiration of solid and liquid food into the respiratory tract, which can lead to life-threatening @entity55 . On this background the care of the elderly @entity1 in nursing homes is a challenge for nurses. The aim of this literature review is to identify suitable screening tools and to evaluate their practicability for nurses' everyday work. The database search was conducted in CINAHL, Ovid Medline and EMBASE. Ten screening tools fitted the selection criteria. Most of them are developed by speech and language therapists and physicians, only two tools are designed by nursing scientists. A swallowing test is part of all screening tools; the target population are @entity64 @entity1 in their acute phase. Other relevant criteria besides the swallowing test are, e. g. the @entity1 ' health status, taking of psychotropic drugs, and posture. All instruments are described as simple to use. They are tested for validity, and sometimes for reliability, but the tools are mostly not appropriate for the use in institutional geriatric care settings. The two instruments developed by nurse scientists are only of limited use in nursing homes, because both instruments were not tested in nursing homes and only one of these tools shows acceptable values of interrater reliability and criterion-related validity. As a result, a screening tool for the target group and a training programme for nurses should be developed.

title: [Risk for XXXX screening tools - a review of the international literature].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'people']

entities_list: @entity2700 :: ('MESH:D003681', 'Disease') :: ['dehydration']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonia']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological disorders']

entities_list: @entity3147 :: ('MESH:D044342', 'Disease') :: ['malnutrition']

entities_list: @entity1282 :: ('MESH:D003680', 'Disease') :: ['dysphagia']

answer: @entity1282 :: (MESH:D003680,Disease) :: ['dysphagia']


abstract: UNASSIGNED: @entity1 with Down syndrome are more susceptible to autoimmune pathologies, in particular endocrine or digestive diseases such as @entity1593 . @entity7017 is another form of digestive autoimmune disease, non-gluten-dependant, more often diagnosed in male neonates with @entity20960 and polyendocrinopathy such as the @entity20960 , @entity12010 , Enteropathy, @entity1112 . It also exists in the adult, but this pathology is less known and therefore frequently under-diagnosed. Clinical manifestations are similar to @entity1593 , but not improved after a gluten-free diet. @entity7017 is frequently associated with other @entity792 , such as @entity1374 , @entity1737 , @entity3230 , as @entity6078 . Pathological analysis of intestinal biopsies can frequently distinguish @entity792 . @entity7017 usually has an important lymphoplasmacytic infiltration of the mucosa and a lack of intraepithelial lymphocytes in the gastrointestinal mucosal surface, while @entity1593 usually has a polymorph infiltration of the mucosa and an important intraepithelial lymphocytes infiltration. Nevertheless, the two pathological patterns may overlap. Here we report the first case of a @entity1 with Down syndrome associated to @entity7017 (initially diagnosed as @entity1593 ), chronic @entity788 and @entity3830 . Even if autoimmune pathologies are much more common in @entity1 with Down syndrome, we would like to report on this rare and original association found in our @entity1 .

title: A Difficult and Rare Diagnosis of XXXX in a @entity1 Affected by Down Syndrome.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatitis']

entities_list: @entity1593 :: ('MESH:D002446', 'Disease') :: ['celiac disease']

entities_list: @entity20960 :: ('MESH:C562780', 'Disease') :: ['Immunodysregulation', 'immunodysregulation']

entities_list: @entity6078 :: ('MESH:D017074', 'Disease') :: ['Common Variable Immunodeficiency']

entities_list: @entity1112 :: ('MESH:D040181', 'Disease') :: ['X-linked syndrome']

entities_list: @entity1737 :: ('MESH:D009157', 'Disease') :: ['myasthenia gravis']

entities_list: @entity7017 :: ('MESH:C538273', 'Disease') :: ['autoimmune enteropathy', 'Autoimmune enteropathy']

entities_list: @entity3830 :: ('MESH:D008178', 'Disease') :: ['cutaneous lupus erythematosus']

entities_list: @entity12010 :: ('MESH:D016884', 'Disease') :: ['Polyendocrinopathy']

entities_list: @entity3230 :: ('MESH:C565469', 'Disease') :: ['lupus or immune deficiencies']

entities_list: @entity792 :: ('MESH:D001327', 'Disease') :: ['autoimmune enteropathy and celiac disease', 'autoimmune diseases']

entities_list: @entity1374 :: ('MESH:D013959', 'Disease') :: ['thyroiditis']

answer: @entity7017 :: (MESH:C538273,Disease) :: ['Autoimmune Enteropathy']


abstract: We report results of a phase II trial of combination of melphalan, @entity6985 , and @entity619 for the treatment of immunoglobulin light chain ( @entity1582 ) @entity2783 . The primary objectives were tolerability and hematologic response rate; secondary objectives were organ responses and survival. Treatment protocol consisted of melphalan 5 mg/m(2)/day for four days, @entity6985 10 mg/day for 21 days and @entity619 20-40 mg once a week every 28 days for a total of 12 cycles. Sixteen subjects were enrolled of whom 14 completed at least 3 cycles and were evaluable for response. Grade 3/4 @entity137 were experienced by 88% (n=14), the most common being myelosuppression (n=7). Dose reductions occurred in 85% (n=12 of 14) of subjects. Hematologic partial and complete responses were achieved by 43% (n=6 of 14) and 7% (n=1 of 14), respectively. The median overall survival has not been reached and median progression-free survival is 24 months. In conclusion, this combination is associated with significant myelosuppression leading to dose modifications and producing minor hematologic responses in @entity1582 . http://clinicaltrials.gov/ @entity16065 /show/NCT00679367.

title: Melphalan, @entity6985 and XXXX for the treatment of immunoglobulin light chain @entity2783 : results of a phase II trial.

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities']

entities_list: @entity2783 :: ('MESH:D000686', 'Disease') :: ['amyloidosis']

entities_list: @entity1582 :: ('MESH:D009101', 'Disease') :: ['AL amyloidosis', 'AL']

entities_list: @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone']

entities_list: @entity6985 :: ('MESH:C467567', 'Chemical') :: ['lenalidomide']

answer: @entity619 :: (MESH:D003907,Chemical) :: ['dexamethasone']


abstract: Regional and overall left ventricular contraction reserve was studied in 14 @entity1 with @entity301 , in 5 healthy subjects and in 4 @entity1 before and after aorto-coronary bypass surgery. Quantification of overall contraction was based on ventricular volumes and ejection fraction. Regional contraction reserve was calculated with the hemiaxis method and a ventricular score. Contraction reserve under @entity1242 and in postextrasystolic beats was compared. For routine quantification of contraction reserve the ventricular score is recommended. For research purposes the hemiaxis method is to be preferred. Postextrasystolic beats are better suited for analysis of contraction reserve than are angiograms following administration of @entity1242 . This is due to the minor expense of the procedure, furthermore, postextrasystolic beats allow better differentiation between contracting and non-contracting areas. Left ventricular contraction reserve is larger in @entity1 with @entity301 , @entity951 and ischemic reactions in the exercise ECG than in control @entity1 . These findings are based on overall and on regional volume parameters. A quantitatively greater improvement in contraction could be provoked in the anterior wall than in the posterior wall. Regional contraction improved significantly in most cases either in the anterior wall or in the posterior wall; rarely it improved simultaneously in both left ventricular regions. In a few cases contraction deteriorated in one area with a simultaneous improvement in the opposite area. Overall and regional ventricular function, as assessed preoperatively by contraction reserve determinations could not be completely regained in normal beats after successful bypass surgery. Differences in the regional contraction reserve seemed to be mainly due to varying degrees of @entity63 and @entity2318 .

title: [Left ventricular contraction reserve in XXXX . Evaluation, quantification and prognostic value (author's transl)].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1242 :: ('MESH:D005996', 'Chemical') :: ['nitroglycerin']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia']

entities_list: @entity301 :: ('MESH:D003327', 'Disease') :: ['coronary heart disease']

entities_list: @entity951 :: ('MESH:D000787', 'Disease') :: ['angina pectoris']

answer: @entity301 :: (MESH:D003327,Disease) :: ['coronary heart disease']


abstract: CONTEXT: High prevalence of "biochemical" @entity1887 ( @entity1887 ) in thalassemics has been reported. However, "clinical" @entity1887 is rare. AIM: The aim was to determine whether @entity701 binding globulin ( @entity8149 ) or tests used in assessing adrenal function contributed to the abnormally high prevalence of biochemical @entity1887 . SETTING: The study was conducted at Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. @entity1 : @entity1 included 56 @entity1 and adolescents with @entity2395 and 44 controls. MAIN OUTCOME MEASURES: Serum @entity8149 and adrenal function test results assessed by 1  g cosyntropin test and insulin tolerance test (ITT) were measured. Free @entity701 index (FCI) calculated by total @entity701 (TC)/ @entity8149 and calculated free @entity701 (cFC) were determined. RESULTS: Mean (sd) @entity8149 levels were comparable between @entity1 and controls [45.2 (11.0) vs. 47.0 (8.6) mg/liter]. Peak TC, FCI, and cFC after @entity5304 test were lower in thalassemics [TC, 15.2 (4.0) vs. 18.9 (3.1)  g/dl; FCI, 3.4 (0.8) vs. 4.2 (1.2)  g/mg, P <0.001; and cFC, 1.03 (0.38) vs. 1.44 (0.61)  g/dl, P = 0.008]. Thirty of 56 thalassemics (53.6%) had @entity1887 , defined as having peak TC of less than 16  g/dl. ITT was performed in 26 of those 30 @entity1 . Five of 26 @entity1 had peak TC after an ITT of at least 20  g/dl. As a result, the estimated frequency of @entity1887 in the entire @entity1 group was reduced by approximately 10%. CONCLUSION: The 1  g cosyntropin test could be an adrenal function screening test in thalassemics. However, for definite diagnosis, ITT should be performed in those having peak total @entity701 of less than 16  g/dl after the 1  g cosyntropin test.

title: High prevalence of "biochemical" XXXX in thalassemics: is it a matter of different testings or decreased @entity701 binding globulin?

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'patient', 'Participants', 'PARTICIPANTS']

entities_list: @entity1887 :: ('MESH:D000309', 'Disease') :: ['adrenal insufficiency', 'AI']

entities_list: @entity5304 :: ('MESH:D003366', 'Chemical') :: ['cosyntropin']

entities_list: @entity701 :: ('MESH:D006854', 'Chemical') :: ['cortisol']

entities_list: @entity2395 :: ('MESH:D013789', 'Disease') :: ['thalassemia']

answer: @entity1887 :: (MESH:D000309,Disease) :: ['adrenal insufficiency']


abstract: The Epidemiology of @entity6 Interventions and Complications (EDIC) is a multicenter longitudinal observational study of the @entity6 Control and Complications Trial (DCCT) cohort. One of the major objectives of EDIC is to study the development and progression of @entity65 disease in type 1 @entity6 . In this study, we evaluated the role of cardiovascular risk factors and antecedent therapy in the DCCT on carotid @entity121 ( @entity121 ) in type 1 @entity6 . At approximately 18 months after the end of the DCCT, high-resolution B-mode ultrasonography was used to assess the carotid arteries of 1,325 @entity1 with type 1 @entity6 , 19-51 years of age, with duration of @entity6 ranging from 6.3 to 26.1 years. An age- and sex-matched nondiabetic population (n = 153) was studied with the same protocol. The ultrasound protocol was carried out in 28 EDIC clinics by centrally trained and certified sonographers using one of three scanning systems. Determination of @entity121 from videotaped images was performed by a single reader at the Central Ultrasound Reading Unit. Univariate associations with greater @entity121 were strongest for older age and longer @entity6 duration, greater waist-to-hip ratio ( @entity1 only), higher blood pressure, higher LDL @entity165 , and smoking. The DCCT therapy group (intensive versus conventional) and HbA1c, measured at the time of the ultrasound or the mean HbA1c during the DCCT, were not significantly related to @entity121 . Multivariate analyses suggest that age, height, smoking, and BMI were the major predictors of common carotid @entity121 , whereas age, smoking, and LDL @entity165 predicted internal carotid @entity121 . There were significant differences between the @entity121 values of the internal carotid artery in the EDIC male cohort and similarly aged male nondiabetic control subjects. There were no significant differences between the @entity121 values in the EDIC female cohort and similarly aged female nondiabetic control subjects. At this point in the planned 10-year follow-up of the DCCT cohort, neither intensive therapy nor HbA1c level appears to influence the early signs of @entity731 . Traditional risk factors, including age, smoking, and LDL @entity165 , were related to @entity121 . As the cohort is only now entering the age interval during which rapid progression and clinical expression of @entity731 are expected, further follow-up will help to determine the role of @entity4854 , and its interaction with other risk factors, on the development of @entity731 .

title: Effect of intensive XXXX treatment on carotid artery wall thickness in the epidemiology of @entity6 interventions and complications. Epidemiology of @entity6 Interventions and Complications (EDIC) Research Group.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'men']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['Diabetes', 'diabetes']

entities_list: @entity4854 :: ('MESH:D006943', 'Disease') :: ['hyperglycemia']

entities_list: @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerosis']

entities_list: @entity121 :: ('MESH:D009135', 'Disease') :: ['IMT', 'intima-media wall thickness']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['atherosclerotic cardiovascular']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

answer: @entity6 :: (MESH:D003920,Disease) :: ['diabetes']


abstract: AIMS: @entity282 is common in hospital-admitted @entity1 . Its management is determined by different therapeutic traditions and by the attitudes of health professionals in each hospital. The aim of this study was to describe the patterns of prescription and administration of analgesic drugs used for @entity282 after abdominal surgery in Spanish hospitals, to know the prevalence and the severity of @entity282 , and to determine the extent of variability in the management of @entity282 among the participating centres. METHODS: The study was a multicentre descriptive cross-sectional drug utilization study in 12 Spanish hospitals. The subjects were an unselected sample of consecutive @entity1 undergoing abdominal surgery, admitted between October 1994 and January 1995. For each @entity1 , information about the surgical procedure and the use of analgesics was prospectively collected. The severity of @entity282 was assessed during the first day after surgery by means of a six-category (none, mild, moderate, severe, very severe, and unbearable) rating scale and a visual analogue scale (VAS). RESULTS: Nine hundred and ninety-three @entity1 (547 @entity1 ) were included. The most common surgical procedures were @entity169 (315, 32%), cholecystectomy (268, 27%), appendectomy (140, 14%), bowel resection (137, 14%), and gastric surgery (58, 6%). Fifty-nine percent of @entity1 (587) received nonopioid analgesics only, 9% (89) received opioid analgesics only, and 27% (263) received both opioid and nonopioid analgesics. The most frequently administered drugs were metamizole (667 @entity1 ) and @entity6882 (213 @entity1 ). Although in the majority of medical orders the administration of analgesics was scheduled at regular time intervals, the majority of actual doses were given 'as-needed'. The average administered daily doses of all analgesics were lower than those prescribed. Thirty-eight percent (371/967) of @entity1 rated their maximum @entity158 on the first day as severe to unbearable. Wide interhospital variability was recorded in the surgical procedures which had been performed, in the analgesics used, and also in the @entity158 scores referred by @entity1 . The percentage of @entity1 in each centre who suffered severe to unbearable @entity158 varied from 22 to 67%. CONCLUSIONS: In Spain many @entity1 still suffer severe @entity158 after abdominal surgery, and this seems to be due to an inadequate use of analgesics. Wide interhospital variability in the management of @entity282 and in its prevalence was also recorded.

title: Management of XXXX in abdominal surgery in Spain. A multicentre drug utilization study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'men']

entities_list: @entity6882 :: ('MESH:D008614', 'Chemical') :: ['pethidine']

entities_list: @entity169 :: ('MESH:D006552', 'Disease') :: ['inguinal hernia repair']

entities_list: @entity282 :: ('MESH:D010149', 'Disease') :: ['postoperative pain', 'Postoperative pain']

answer: @entity282 :: (MESH:D010149,Disease) :: ['postoperative pain']


abstract: BACKGROUND: The main goal of this study was to improve diagnostic and predictive value of low and moderately elevated @entity1851 ( @entity1851 ) in @entity1 with @entity1187 ( @entity1187 ), related to noninvasive clinical parameters, in order to improve and prolong @entity1 life with low or no additional costs. MATERIAL/METHODS: A prospective, open clinical study was conducted at the University Hospital Split, Croatia with 112 @entity1 with @entity1187 and low or moderately elevated @entity1851 (<3.0 mg/L). After diagnosing @entity1187 , data on physical activity, @entity167 consumption, and functional status were recorded. Anthropometric measurements were made. Blood and urine samples were taken for analyses. Electrocardiographic, ergometric, and echocardiographic testing was performed. A total of 72 parameters were monitored at the time of hospital admission in @entity1187 @entity1 to analyze which ones could predict disease outcome at the end of follow-up in @entity1 with low or moderately elevated @entity1851 . @entity1 were followed up for 2 years. RESULTS: The variables that were predictive of major adverse @entity299 (MACE) within 2 years of @entity1187 hospitalization were hemoglobin, @entity2002 , antithrombin III, @entity165 levels, brain natriuretic peptide, and microalbuminuria. @entity1187 @entity1 with @entity29726 .0 mg/L had significantly higher risk of developing MACE within 2 years if >= 50% of the 8 key parameters were outside the reference values. CONCLUSIONS: Major adverse @entity299 can be predicted in @entity1 with @entity1187 whose @entity1851 values are low or moderately elevated.

title: Prognostic value of low and moderately elevated XXXX in @entity1187 : a 2-year follow-up study.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity1187 :: ('MESH:D054058', 'Disease') :: ['ACS', 'acute coronary syndrome']

entities_list: @entity167 :: ('CHEBI:16236', 'Chemical') :: ['alcohol']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac events']

entities_list: @entity1851 :: ('1401', 'Gene') :: ['C-reactive protein', 'CRP']

answer: @entity1851 :: (1401,Gene) :: ['C-reactive protein']


abstract: OBJECTIVE: To evaluate clinical effectiveness, color rebound and sensitivity of 22% @entity12946 (CP) with 3% @entity3164 . METHODS: Twenty-one @entity1 were enrolled and treated overnight for 2 weeks with 22% CP (Venus White, Heraeus Kulzer). Visual color measurement was performed and expressed in shade guide units (SGU) of Vita Classical (VC) and Vita Bleachedguide 3D Master (BG) shade guides. Instrumental color measurements were performed using an intraoral spectrophotometer (Vita Easyshade Compact, EC). Color measurements were taken on a @entity235 and central incisor at baseline, 2, 3, and 4 weeks. @entity1 documented sensitivity and data were analysed with Wilcoxon and Bonferroni correction at the 0.05 level of significance. RESULTS: Mean BG SGU difference immediately, 1 and 2 weeks postbleaching compared to baseline was 4.9 (2.1), 4.5 (2.2) and 4.6 (2.0), respectively. Corresponding VC values were 7.0 (3.5), 6.4 (3.3) and 6.5 (3.4), while corresponding   E* values were 8.3 (4.1), 8.1 (4.0) and 7.9 (3.5). For visual shade evaluation there was a significant decrease in SGU from baseline and each subsequent week, p<0.001. There was no difference between week 3 and week 4 using VC or BG. For instrumental color measurements, there was no difference from week 2 to week 3 for @entity235 and generally no difference between week 3 and week 4 for incisors. CONCLUSIONS: Visual and instrumental evaluation showed rebound occurred 1 week postbleaching with 22% @entity12946 and 3% @entity3164 . In general, color was stable at 2 weeks postbleaching. @entity1 reported low sensitivity levels with a mean value of below 2 on a 0-10 scale. CLINICAL SIGNIFICANCE: This study demonstrates efficacy with overnight usage of 22% @entity12946 with 3% @entity3164 and demonstrates postbleaching color is stable at two weeks with @entity258 .

title: Clinical effectiveness and sensitivity with overnight use of 22% XXXX gel.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'Participants']

entities_list: @entity235 :: ('9615', 'Species') :: ['canine', 'canines']

entities_list: @entity12946 :: ('MESH:C009096', 'Chemical') :: ['carbamide peroxide']

entities_list: @entity3164 :: ('MESH:C023844', 'Chemical') :: ['potassium nitrate']

entities_list: @entity258 :: ('MESH:D009800', 'Disease') :: ['low tooth sensitivity']

answer: @entity12946 :: (MESH:C009096,Chemical) :: ['carbamide peroxide']


abstract: STUDY OBJECTIVE: The aim of the study was to evaluate in @entity101 subjects the longitudinal pressure drop and segmental resistance in a large artery in relation to shearing forces of the circulating blood column at the arterial wall. DESIGN: Arterial diameter, blood velocity, and flow were measured in the brachial artery using pulsed Doppler apparatus. Blood viscosity was measured at 96 s-1 with a low shear viscometer. Segmental resistance per unit arterial length was calculated using the basic Poiseuille resistance expression from the ratio between blood viscosity and the fourth power of arterial diameter. Longitudinal pressure drop was deduced as the product between segmental resistance and blood flow. The Poiseuille model of velocity distribution also enabled wall shear rate and stress to be calculated from the ratio between blood velocity and arterial diameter and from the product between shear rate and blood viscosity respectively. @entity1 : 19 ambulatory male @entity1 with mild to moderate @entity101 and 11 normotensive male controls of similar age were studied. RESULTS: Compared to controls, @entity101 @entity1 had higher arterial diameter (p less than 0.001) lower blood velocity (p less than 0.05), higher blood viscosity (p less than 0.01), lower segmental resistance and pressure drop (p less than 0.001, p less than 0.01) and lower shear rate and stress (p less than 0.01, p less than 0.05). A negative correlation existed in the overall normotensive and @entity101 population between pressure drop and mean blood pressure (r = -0.55, p less than 0.01). CONCLUSION: The @entity101 state is associated with a clear reduction in large artery segmental resistance and longitudinal pressure drop concomitantly with a decrease in shear conditions at the arterial wall. The mechanisms of reduced resistance and pressure drop are related to decreased wall shear and increased diameter of the artery, both of which reduce the frictional forces at the blood-arterial wall interface.

title: Non-invasive evaluation of segmental pressure drop and resistance in large arteries in XXXX based on a Poiseuille model of intra-arterial velocity distribution.

entities_list: @entity1 :: ('9606', 'Species') :: ['PATIENTS', 'patients']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertensive', 'hypertension']

answer: @entity1 :: (9606,Species) :: ['humans']


abstract: OBJECTIVE: To present a case series of ipilimumab-related @entity1887 . METHODS: In this cases series, we review the presentation, evaluation, diagnosis, and management of @entity1 with advanced @entity320 who received ipilimumab and were referred to our endocrinology clinic for evaluation of hormonal abnormalities. RESULTS: Seven @entity1 presented with symptoms, signs, or biochemical evidence of @entity1887 6 to 12 weeks after starting ipilimumab therapy. Ipilimumab is a @entity4386 ( @entity4386 ) monoclonal antibody that is approved for the treatment of @entity320 and has widespread use for this disease. All 7 @entity1 had biochemical evidence of profound @entity1887 . @entity1374 , @entity6126 , and low insulinlike growth factor 1 levels were seen in a subset of @entity1 . Only 2 @entity1 had abnormal findings on pituitary magnetic resonance imaging. Posterior pituitary function remained normal. CONCLUSIONS: Our findings suggest that the enhanced immune response associated with ipilimumab therapy may have a predilection for corticotroph and possibly thyrotroph cells. We recommend periodic hypothalamic-pituitary-adrenal axis monitoring for @entity1 on this therapy.

title: Association of ipilimumab therapy for advanced @entity320 with XXXX : a case series.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1887 :: ('MESH:D000309', 'Disease') :: ['adrenal insufficiency', 'secondary adrenal insufficiency']

entities_list: @entity6126 :: ('MESH:D007006', 'Disease') :: ['central hypogonadism']

entities_list: @entity4386 :: ('1493', 'Gene') :: ['cytotoxic T-lymphocyte antigen 4', 'CTLA-4']

entities_list: @entity320 :: ('MESH:D008545', 'Disease') :: ['melanoma', 'metastatic melanoma']

entities_list: @entity1374 :: ('MESH:D013959', 'Disease') :: ['Thyroid function abnormalities']

answer: @entity1887 :: (MESH:D000309,Disease) :: ['secondary adrenal insufficiency']


abstract: We used immunocytochemistry to locate two @entity460 binding proteins, calbindin ( @entity14137 ) and @entity7053 (PV), in the retina of @entity2083 , frog, @entity1573 , @entity35 , @entity840 , @entity235 , and @entity1 . The location of @entity14137 depended on the type of dominant photoreceptor cells in birds and mammals. In cone-dominant retinas such as those of the @entity1573 , @entity14137 -like immunoreactivity was found in the cones, cone bipolars, and @entity4494 cells. Amacrine cells 5-12 microns across were also labeled. In rod-dominant retinas, such as those of the @entity35 , @entity840 , and @entity235 , horizontal cells, small amacrine cells (about 6 microns across), and cells in the @entity4494 cell layer were labeled. In the @entity1 retina, which has both cones and rods in abundance, cones, cone bipolars, @entity4494 cells, horizontal cells, and small and large amacrine cells were labeled. In the frog and @entity2083 , the level of @entity14137 -like immunoreactivity was low. In the frog, a few cones, amacrine cells, and cells in the @entity4494 cell layer were labeled. No immunoreactive structures were seen in the @entity2083 retina. PV-like immunoreactivity was found in chicks, @entity35 , and @entity235 . No such immunoreactive structures were seen in the other species. In the @entity1573 , only amacrine cells were labeled. In the @entity35 , amacrine cells and several displaced amacrine cells were labeled. In the @entity235 , in addition to amacrine cells and displaced amacrine cells, horizontal cells were strongly labeled. Thus, PV-like immunoreactivity was found in those elements relating to the modulation of the main pathway of the visual transmission system.

title: Localization of two @entity460 binding proteins, calbindin (28 kD) and XXXX (12 kD), in the vertebrate retina.

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

answer: @entity7053 :: (25269(Tax:10116),Gene) :: ['parvalbumin']


abstract: PURPOSE: One goal of the @entity1 -Reported Outcomes Measurement Information System (PROMIS) is to develop a measure of sexual functioning that broadens the definition of sexual activity and incorporates items that reflect constructs identified as important by @entity1 with @entity5 . We describe how cognitive interviews improved the quality of the items and discuss remaining challenges to assessing sexual functioning in research with @entity5 populations. METHODS: We conducted 39 cognitive interviews of @entity1 with @entity5 and survivors on the topic of sexual experience. Each of the 83 candidate items was seen by 5-24 @entity1 . @entity1 included both @entity1 and @entity1 and varied by @entity5 type, treatment trajectory, race, and literacy level. Significantly revised items were retested in subsequent interviews. RESULTS: Cognitive interviews provided useful feedback about the relevance, sensitivity, appropriateness, and clarity of the items. @entity1 identified broad terms (e.g., "sex life") to assess sexual experience and exposed the challenges of measuring sexual functioning consistently, considering both adjusted and unadjusted sexual experiences. CONCLUSIONS: Cognitive interviews were critical for item refinement in the development of the PROMIS measure of sexual function. Efforts are underway to validate the measure in larger @entity5 populations.

title: Using cognitive interviews to evaluate items for measuring sexual functioning across XXXX populations: improvements and remaining challenges.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'women', 'patients', 'Participants', 'Patient', 'men']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

answer: @entity5 :: (MESH:D009369,Disease) :: ['cancer']


abstract: OBJECTIVE: (1) Characterize risk factors for subsequent tonsillectomy in pediatric @entity1 undergoing primary adenoidectomy for @entity1224 . (2) Compare rates of subsequent tonsillectomy between adenoidectomy @entity1 with and without @entity1224 . STUDY DESIGN: Historical cohort study with a nested case-control study. Cohort data were analyzed using Kaplan-Meier plots and a multiple regression model. Case-control data were analyzed using logistic regression. SUBJECTS AND METHODS: @entity1 undergoing adenoidectomy without tonsillectomy at the University of Missouri between 1995 and 2010 were identified using billing records and selected chart review. A nested case-control study with detailed chart review was conducted to determine predictors of subsequent tonsillectomy in @entity1 with @entity1224 . RESULTS: Of 1291 @entity1 identified in the historical cohort, 7.8% later underwent tonsillectomy. Age younger than 3 years (P = .027), female sex (P < .0001), and @entity1224 (P = .001) were found to be significant predictors of subsequent tonsillectomy. In the nested case-control study, potential predictors investigated included adenoidectomy indications, symptoms, smoke exposure, weight, comorbidities, and tonsil size at the time of adenoidectomy. Of these, only tonsil size was significant, with an increased odds of future tonsillectomy of 2.5 (P = .01) for each unit increase in tonsil size. CONCLUSION: @entity1 undergoing adenoidectomy for @entity1224 are likely to be at an increased risk of subsequent tonsillectomy when compared with those with other indications. Within this subgroup of @entity1 with @entity1224 , young age, female sex, and large tonsil size may further increase the risk of subsequent tonsillectomy.

title: Predictors of tonsillectomy after previous adenoidectomy for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Patients']

entities_list: @entity1224 :: ('MESH:D000402', 'Disease') :: ['upper airway obstruction']

answer: @entity1224 :: (MESH:D000402,Disease) :: ['upper airway obstruction']


abstract: AIMS: We aimed to investigate the relationship among @entity9961 / @entity7802 expression, lymphatic @entity3 and @entity1 prognosis in @entity356 . MATERIAL AND METHODS: @entity9961 and @entity7802 expression in @entity356 tissues obtained from 204 @entity1 who underwent curative gastrectomy (105 cases presented with lymph node @entity3 and 99 cases without @entity3 ) was examined immunohistochemically. There was no significant difference in the other clinicopathologic variables except for postoperative pathological @entity5 stage (pT) and TNM stage between the two groups. The results were statistically processed. RESULTS: The results showed that @entity9961 was located mainly in the cytoplasm of @entity5 cells and @entity7802 was found predominantly in the endothelium of lymphatic vessels. @entity9961 and @entity7802 expression was more frequent in @entity356 tissues than that in normal gastric tissues, 54.90% and 35.29% respectively, which revealed that the expression of @entity9961 and @entity7802 was significantly stronger in @entity1 with lymph node @entity3 than in those without @entity3 . @entity1 who had positive staining for @entity9961 showed significantly less favorable survival rates compared with @entity1 who had negative staining for @entity9961 . The survival rates of @entity1 who had positive staining for @entity7802 also were significantly lower compared with @entity1 who had negative staining for @entity7802 . @entity1 who had positive staining for both @entity9961 and @entity7802 exhibited the most unfavorable prognosis. Multivariate analysis demonstrated that the expression of @entity9961 and @entity7802 was an independent prognostic determinant. In addition, faint to moderate @entity9961 expression was detected in normal gastric epithelial cells (18/204, 8.9%). CONCLUSIONS: @entity9961 and @entity7802 expression could serve as a prognostic biomarker in @entity1 with @entity356 .

title: The effect of the expression of vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 on the clinical outcome in XXXX with @entity356 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric carcinoma']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: OBJECTIVES: To test the hypothesis that the geographic pattern of mortality with @entity303 coded on the @entity204 certificate varies according to race and that racial differences vary according to geography in the United States. DESIGN: Analysis of the U.S. multiple-cause-of- @entity204 files for 1999 to 2004. SETTING: United States. @entity1 : Decedents with @entity303 coded as underlying or contributing cause of @entity204 on the @entity204 certificate. MEASUREMENTS: Age-adjusted @entity204 rates for U.S. Census geographic divisions for blacks and whites aged 65 and older. RESULTS: From 1999 to 2004, the U.S. age-adjusted annual @entity204 rate per 100,000 for @entity303 was 628 in blacks and 647 in whites. The difference between rates in blacks and whites ranged from -130 deaths per 100,000 (-36%) in the Middle Atlantic region to +55 (+8%) in the South Atlantic division. Blacks had higher rates in three divisions and whites in five. In the Middle Atlantic and in the United States as a whole, blacks were relatively more likely to receive a diagnosis of unspecified @entity303 or @entity195 (66%) than @entity195 (30%) than whites (58% and 41%, respectively). CONCLUSION: Although overall rates were similar, geographic variation in racial differences in rates of @entity204 with @entity303 occurred between U.S. regions. Further research is needed to assess geographic and racial variation in artifacts of certification versus biological variation as possible causes of variation to enhance utility of mortality data for disease monitoring and health-disparities research.

title: Differences in mortality associated with XXXX in U.S. blacks and whites.

entities_list: @entity303 :: ('MESH:D003704', 'Disease') :: ['dementia']

entities_list: @entity1 :: ('9606', 'Species') :: ['PARTICIPANTS']

entities_list: @entity195 :: ('MESH:D000544', 'Disease') :: ["Alzheimer's disease", 'senility']

answer: @entity303 :: (MESH:D003704,Disease) :: ['dementia']


abstract: 1. The inhibitory effects of @entity1246 ( @entity1246 ), the GABAA receptor agonist @entity27201 and the GABAB receptor agonist (+/-)- @entity1772 were investigated on circular muscle strips of the @entity235 terminal ileum and ileocolonic junction. 2. In the presence of @entity3897 , @entity1246 and @entity27201 induced concentration-dependent relaxations, similar to the non-adrenergic non-cholinergic (NANC)-mediated relaxations evoked by electrical stimulation or by @entity934 . The ileocolonic junction was more sensitive to @entity1246 and @entity27201 than the ileum. @entity1772 had no effect. Cross desensitization only occurred between @entity1246 and @entity27201 . 3. The GABAA receptor antagonist @entity1027 shifted the concentration-response curves to @entity1246 and @entity27201 to the right. The maximal relaxation to @entity1246 remained unaffected. 4. @entity1246 -induced relaxations were not inhibited by @entity6839 , @entity2997 , @entity2211 , @entity4033 and desensitization to @entity855 , but were abolished by @entity1022 . 5. @entity1027 , and pretreatment with @entity1246 or @entity1772 had no effect on the NANC-evoked relaxations to electrical stimulation and @entity934 . 6. In conclusion, @entity1246 stimulates GABAA receptors located on inhibitory NANC neurones in the @entity235 ileocolonic junction. Our results suggest that it is unlikely that @entity1246 is the final inhibitory NANC neurotransmitter.

title: GABAA receptor-mediated stimulation of non-adrenergic non-cholinergic neurones in the XXXX ileocolonic junction.

entities_list: @entity2997 :: ('MESH:D006145', 'Chemical') :: ['guanethidine']

entities_list: @entity4033 :: ('MESH:D018738', 'Chemical') :: ['hexamethonium']

entities_list: @entity27201 :: ('MESH:C001355', 'Chemical') :: ['homotaurine']

entities_list: @entity1246 :: ('MESH:D005680', 'Chemical') :: ['gamma-aminobutyric acid', 'GABA']

entities_list: @entity1027 :: ('MESH:D001640', 'Chemical') :: ['bicuculline', 'Bicuculline']

entities_list: @entity1022 :: ('MESH:D013779', 'Chemical') :: ['tetrodotoxin']

entities_list: @entity3897 :: ('MESH:D001285', 'Chemical') :: ['atropine']

entities_list: @entity2211 :: ('MESH:D004294', 'Chemical') :: ['domperidone']

entities_list: @entity934 :: ('MESH:D000109', 'Chemical') :: ['acetylcholine']

answer: @entity235 :: (9615,Species) :: ['dog']


abstract: BACKGROUND: Endoscopic clipping for closing a @entity292 created by surgery is often difficult because of the combination of a wide orifice and @entity82 . Creating holes for prongs of a clip may constitute a new endoscopic clipping technique for closing the wide orifice of a @entity292 . OBJECTIVE: To assess the feasibility of performing the endoscopic hole and clipping technique (EHCT). DESIGN: Experimental pilot study. SETTING: Tertiary-care referral center. @entity1 : This study involved 1 @entity1 who underwent EHCT. INTERVENTIONS: EHCT was performed. MAIN OUTCOME MEASUREMENTS: Technical success and procedural complications of EHCT. RESULTS: Immediately after the procedure, drainage decreased dramatically and finally decreased to 0 mL/d. There was no evidence of a leak on fluoroscopic examination, and upon 4-month follow-up, we found that no symptoms had developed in the @entity1 . LIMITATIONS: Single- @entity1 pilot study. CONCLUSIONS: EHCT is very simple and efficient. EHCT can be applied as a means of closing the orifice of a @entity86 that is not easily managed by simple endoscopic clipping.

title: Endoscopic hole and clipping technique: a novel technique for closing the wide orifice of a XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patient', 'PATIENT']

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis']

entities_list: @entity86 :: ('MESH:D019106', 'Disease') :: ['postoperative fistula']

answer: @entity86 :: (MESH:D019106,Disease) :: ['postoperative fistula']


abstract: IMPORTANCE: The value of microRNAs (miRNAs) as biomarkers has been investigated in various clinical contexts. Initial small-scale studies suggested that miRNAs might be useful indicators of outcome after @entity1167 . OBJECTIVE: To address the prognostic value of circulating miRNAs in a large cohort of @entity772 @entity1 with out-of-hospital @entity1167 . DESIGN, SETTING, AND @entity1 : This substudy of the Target Temperature Management After Cardiac Arrest (TTM) trial, a multicenter randomized, parallel-group, assessor-blinded clinical trial, compared the 6-month neurologic outcomes and survival of @entity1 with @entity1167 after targeted temperature management at 33  C or 36  C. Five hundred seventy-nine @entity1 who survived the first 24 hours after the return of spontaneous circulation and who had blood samples available for miRNA assessment were enrolled from 29 intensive care units in 9 countries from November 11, 2010, to January 10, 2013. Final follow-up was completed on July 3, 2013, and data were assessed from February 1, 2014, to February 1, 2016. INTERVENTIONS: Blood sampling at 48 hours after the return of spontaneous circulation. MAIN OUTCOMES AND MEASURES: The primary end point was poor neurologic outcome at 6 months (cerebral performance category score, 3 [severe neurologic sequelae], 4 [coma], or 5 [death]). The secondary end point was survival until the end of the trial. Circulating levels of miRNAs were measured by sequencing and polymerase chain reaction. RESULTS: Of the 579 @entity1 (265 @entity1 [80.3%]; mean [SD] age, 63 [12] years), 304 @entity1 (52.5%) had a poor neurologic outcome at 6 months. In the discovery phase with short RNA sequencing in 50 @entity1 , the brain-enriched @entity36200 level was identified as a candidate prognostic variable for neurologic outcomes. In the validation cohort of 529 @entity1 , mean (SD) levels of @entity36200 were higher in @entity1 with a poor outcome (8408 [12 465] copies/  L) compared with @entity1 with a good outcome (1842 [3025] copies/ L; P   <   .001). The @entity36200 level was significantly associated with neurologic outcomes in the univariable analysis (odds ratio, 6.72; 95% CI, 4.53-9.97). In multivariable analyses using logistic regression, @entity36200 levels were independently associated with neurologic outcomes (odds ratio, 1.62; 95% CI, 1.13-2.32). In Cox proportional hazards models, higher levels of @entity36200 were significantly associated with lower survival (hazard ratio, 1.63; 95% CI, 1.37-1.93). CONCLUSIONS AND RELEVANCE: Levels of @entity36200 can be used as prognostication tools for neurologic outcome and survival after out-of-hospital @entity1167 . Thus, miRNA levels may aid in tailoring health care for @entity1 with @entity1167 . TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01020916.

title: Association of Circulating MicroRNA-124-3p Levels With Outcomes After XXXX : A Substudy of a Randomized Clinical Trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PARTICIPANTS', 'men']

entities_list: @entity772 :: ('MESH:D003128', 'Disease') :: ['comatose']

entities_list: @entity1167 :: ('MESH:D006323', 'Disease') :: ['cardiac arrest']

answer: @entity1167 :: (MESH:D006323,Disease) :: ['Out-of-Hospital Cardiac Arrest']


abstract: PURPOSE: PD-1 inhibitors are established agents in the management of @entity1149 ( @entity1149 ); however, only a subset of @entity1 derives clinical benefit. To determine the activity of PD-1/ @entity4634 inhibitors within clinically relevant molecular subgroups, we retrospectively evaluated response patterns among @entity470 -mutant, @entity706 kinase ( @entity7041 )-positive, and @entity470 wild-type/ @entity7041 -negative @entity1 . EXPERIMENTAL DESIGN: We identified 58 @entity1 treated with PD-1/ @entity4634 inhibitors. Objective response rates (ORR) were assessed using RECIST v1.1. @entity4634 expression and @entity405 (+) @entity5 -infiltrating lymphocytes (TIL) were evaluated by IHC. RESULTS: Objective responses were observed in 1 of 28 (3.6%) @entity470 -mutant or @entity7041 -positive @entity1 versus 7 of 30 (23.3%) @entity470 wild-type and @entity7041 -negative/unknown @entity1 (P = 0.053). The ORR among never- or light- (<= 10 pack years) smokers was 4.2% versus 20.6% among heavy smokers (P = 0.123). In an independent cohort of advanced @entity470 -mutant (N = 68) and @entity7041 -positive (N = 27) @entity1 , @entity4634 expression was observed in 24%/16%/11% and 63%/47%/26% of pre- @entity4149 kinase inhibitor (TKI) biopsies using cutoffs of >= 1%, >= 5%, and >= 50% @entity5 cell staining, respectively. Among @entity470 -mutant @entity1 with paired, pre- and post-TKI-resistant biopsies (N = 57), @entity4634 expression levels changed after resistance in 16 (28%) @entity1 . Concurrent @entity4634 expression (>= 5%) and high levels of @entity405 (+) TILs (grade >= 2) were observed in only 1 pretreatment (2.1%) and 5 resistant (11.6%) @entity470 -mutant specimens and was not observed in any @entity7041 -positive, pre- or post-TKI specimens. CONCLUSIONS: NSCLCs harboring @entity470 mutations or @entity7041 rearrangements are associated with low ORRs to PD-1/ @entity4634 inhibitors. Low rates of concurrent @entity4634 expression and @entity405 (+) TILs within the @entity5 microenvironment may underlie these clinical observations. Clin Cancer Res; 22(18); 4585-93.   2016 AACRSee related commentary by Gettinger and Politi, p. 4539.

title: EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in XXXX : A Retrospective Analysis.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity706 :: ('MESH:D008223', 'Disease') :: ['anaplastic lymphoma']

entities_list: @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer']

answer: @entity1149 :: (MESH:D002289,Disease) :: ['Non-Small Cell Lung Cancer']


abstract: 307 @entity1 with @entity764 were treated in an outpatient clinic during a three month period. Ten @entity1 developed complications such as hemothorax, @entity358 , or late complications such as @entity55 . 21 @entity1 were hospitalized after initial evaluation. Two @entity1 died. @entity158 was a symptom in 306 of the 307 @entity1 . Other symptoms were coughing, hempoptysis, @entity221 , @entity390 . Complications increased in 40 @entity1 , with other symptoms or signs in addition to @entity158 . These other symptoms had a 40% positive and 95% negative predictive value as regards complications. 45 out of 114 @entity1 had a pathological chest x-ray. Positive chest x-ray had a 40% positive and 94% negative predictive value as regards complications. In four @entity1 (1.3%) complicating injuries were not identified initially. Five of 24 @entity1 (21%) were hospitalized unnecessarily. Chest x-ray should be performed in @entity1 with additional symptoms and signs. @entity1 with no signs in addition to chest wall tenderness can be observed at home.

title: [Ambulatory evaluation and treatment of blunt XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['atelectases and pneumonia']

entities_list: @entity764 :: ('MESH:D013898', 'Disease') :: ['chest injuries']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['pneumothorax and lung contusion']

answer: @entity764 :: (MESH:D013898,Disease) :: ['thoracic injuries']


abstract: BACKGROUND: A variety of @entity2746 ( @entity164 ) develops a broad spectrum of both @entity2055 . Cognitive and affective changes are one such non-ataxia symptoms, but have been described only in hereditary SCAs with exonic CAG gene expansion. METHODS: We newly found intronic hexanucleotide GGCCTG gene expansion in @entity35031 gene as the causative mutation (= @entity35031 ) in nine unrelated Japanese @entity164 originating from Asida river area in the western part of Japan, thus nicknamed Asidan for this mutation. These @entity1 show unique clinical balance of @entity6447 and @entity4681 ( @entity4681 ), locating on the crossroad of these two diseases. In the nine families, 14 @entity1 were clinically examined and genetically confirmed to Asidan. In the present study, we examined cognitive and affective analyses on 12 @entity1 (seven @entity1 and five @entity1 ) who agreed to join the examination with average age at onset of 53.1    3.2 years, average duration of 12.1    5.2 years, and current average age at 65.1    6.2 years. RESULTS: The 12 Asidan @entity1 demonstrated a significant decrease in their frontal executive functions measured by frontal assessment battery (FAB) and Montreal cognitive assessment (MoCA) compared with age- and gender-matched controls, whilst mini-mental state examination (MMSE) and Hasegawa @entity303 score-revised (HDS-R) were within normal range. The decline of frontal executive function was related to their disease duration and scale for the assessment and rating of ataxias ( @entity25136 ). They also demonstrated mild @entity308 and apathy. Single-photon emission tomography (SPECT) analysis showed that these Asidan @entity1 showed decline of regional cerebral blood flow (rCBF) in a particular areas of cerebral cortices such as Brodmann areas 24 and 44-46. CONCLUSION: These data suggest that the @entity1 with Asidan mutation show unique cognitive and affective characteristics different from other hereditary SCAs with exonal CAG expansion or @entity4681 .

title: Cognitive and affective impairments of a novel @entity164 / XXXX crossroad mutation Asidan.

entities_list: @entity1 :: ('9606', 'Species') :: ['men', 'women', 'patients']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

entities_list: @entity303 :: ('MESH:D003704', 'Disease') :: ['dementia']

entities_list: @entity4681 :: ('MESH:D016472', 'Disease') :: ['motor neuron disease', 'MND']

entities_list: @entity164 :: ('MESH:D017827', 'Disease') :: ['SCA', 'familial SCA']

entities_list: @entity6447 :: ('MESH:D002524', 'Disease') :: ['cerebellar ataxia']

entities_list: @entity2746 :: ('MESH:D013132', 'Disease') :: ['hereditary spinocerebellar ataxia']

entities_list: @entity2055 :: ('MESH:D001259', 'Disease') :: ['ataxia and non-ataxia symptoms']

answer: @entity4681 :: (MESH:D016472,Disease) :: ['MND']


abstract: The inflammasome has been recently implicated in @entity28 -associated dys-metabolism. However, of its products, the specific role of @entity635 was clinically demonstrated to mediate only the pancreatic beta-cell demise, and in @entity19 mainly the intra-hepatic manifestations of @entity28 . Yet, it remains largely unknown if @entity635 , a cytokine believed to mainly function locally, could regulate dysfunctional inter-organ crosstalk in @entity28 . Here we show that High-fat-fed (HFF) @entity19 exhibited a preferential increase of @entity635 in portal compared to systemic blood. Moreover, portally-drained mesenteric fat transplantation from IL-1bKO donors resulted in lower @entity2388 - @entity413 flux compared to @entity19 receiving @entity164 ( @entity164 ) transplant. These results raised a putative endocrine function for visceral fat-derived @entity635 in regulating hepatic gluconeogenic flux. IL-1bKO @entity19 on HFF exhibited only a minor or no increase in adipose expression of pro-inflammatory genes (including macrophage M1 markers), @entity9675 -positive crown-like structures and @entity3804 -F4/80-double-positive macrophages, all of which were markedly increased in @entity164 -HFF @entity19 . Further consistent with autocrine/paracrine functions of @entity635 within adipose tissue, adipose tissue macrophage lipid content was increased in @entity164 -HFF @entity19 , but significantly less in IL-1bKO @entity19 . Ex-vivo, adipose explants co-cultured with primary hepatocytes from @entity164 or IL-1-receptor (IL-1RI)-KO @entity19 suggested only a minor direct effect of adipose-derived @entity635 on hepatocyte insulin resistance. Importantly, although IL-1bKOs gained weight similarly to @entity164 -HFF, they had larger fat depots with similar degree of adipocyte @entity1184 . Furthermore, adipogenesis genes and markers (pparg, cepba, @entity23678 , @entity3240 ) that were decreased by HFF in @entity164 , were paradoxically elevated in IL-1bKO-HFF @entity19 . These local alterations in adipose tissue @entity32 and expansion correlated with a lower liver size, less @entity1560 , and preserved insulin sensitivity. Collectively, we demonstrate that by promoting @entity32 and limiting fat tissue expandability, @entity635 supports ectopic fat accumulation in hepatocytes and adipose-tissue macrophages, contributing to @entity409 in nutritional @entity28 .

title: @entity635 regulates fat-liver crosstalk in @entity28 by auto-paracrine modulation of adipose tissue XXXX and expandability.

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['adipose inflammation', 'inflammation']

entities_list: @entity1560 :: ('MESH:D005234', 'Disease') :: ['hepatic steatosis']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity']

entities_list: @entity1184 :: ('MESH:D006984', 'Disease') :: ['hypertrophy']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['impaired fat-liver crosstalk']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

entities_list: @entity2388 :: ('MESH:D019289', 'Chemical') :: ['pyruvate']

answer: @entity32 :: (MESH:D007249,Disease) :: ['inflammation']


abstract: Rhythm conversion in @entity1 with post-thyrotoxic @entity955 ( @entity955 ) has been performed with @entity7306 in order to evaluate the conversion rate and to test its effect on the maintenance of sinus rhythm after cardioversion. The duration of @entity955 ranged from 9 to 122 months (mean 31.8 months). Of 81 @entity1 , 12 (15%) with relatively short duration @entity955 were converted to sinus rhythm with @entity7306 . The remaining 69 @entity1 required DC cardioversion, which restored sinus rhythm in 58 @entity1 . The 58 DC-converted @entity1 were divided into two groups: a @entity7306 group (D group) and a non- @entity7306 group (non-D group). The D group received @entity7306 300 mg per day for 3 months after DC cardioversion and the non-D group did not receive anti-arrhythmic drugs. During the early observation period, only one @entity1 relapsed in the D group into @entity955 , but 5 successive @entity1 in the non-D group reverted to @entity955 , forcing discontinuation of the non-D protocol. A second DC cardioversion performed on 3 of those 5 @entity1 was followed by maintenance therapy with @entity7306 300 mg per day, and they remained in sinus rhythm. With the inclusion of those three subjects, sinus rhythm was still present in 44 of the total of 58 @entity1 converted by DC (76%) at the time of follow-up (64 months). Thus, @entity7306 was effective in rhythm conversion and it was essential for the maintenance of sinus rhythm after cardioversion in @entity1 with post-thyrotoxic @entity955 .

title: Efficacy of XXXX in conversion and prophylaxis of post-thyrotoxic @entity955 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity7306 :: ('MESH:D004206', 'Chemical') :: ['disopyramide']

entities_list: @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation', 'AF']

answer: @entity7306 :: (MESH:D004206,Chemical) :: ['disopyramide']


abstract: Malformations and increased mortality due to @entity281 by the digenetic trematode, Riberioa ondatrae have been reported for many species of amphibians. Severe @entity600 have also been reported in the Common Hourglass Tree Frog, Polypedates cruciger induced by pleurolophocercous cercariae in Sri Lanka in addition to the changes in the behaviour, development and survival of the host. We exposed pre-limb bud stage tadpoles (Gosner stages 25-26) of the @entity29877 , @entity29877 to the same pleurolophocercous type cercariae under laboratory conditions. Molecular and morphological identification showed that these cercariae belonged Acanthostomum burminis infecting freshwater snakes as definitive hosts. These cercariae induced @entity600 (27.8%) and reduced survival to metamorphosis (53.8%). The magnitude of the effects increased with the dose of cercariae. @entity600 were mainly axial, such as @entity1635 and @entity1513 . Severe @entity4218 such as extra or missing limbs as reported for amphibians exposed to R. ondatrae were not observed in the @entity29877 . Same authors reported a higher percentage of @entity600 previously when P. cruciger was exposed to the cercariae A. burminis compared to @entity29877 . However, tadpoles of @entity29877 , which are smaller compared to those of P. cruciger, experienced higher mortality than P. cruciger tadpoles. @entity2439 induced @entity600 and mortality in amphibians are highly variable and depend on multiple factors such as host species differences such as resistance to @entity281 and tolerance, life-history characteristics such as size at metamorphosis and length of the metamorphosis period, and other factors such as size of the amphibian at the time of trematode exposure.

title: Malformations and mortality in the XXXX induced by exposure to pleurolophocercous cercariae (Trematoda: Cryptogonimidae).

entities_list: @entity4218 :: ('MESH:D017880', 'Disease') :: ['limb malformations']

entities_list: @entity1635 :: ('MESH:D012600', 'Disease') :: ['scoliosis']

entities_list: @entity600 :: ('MESH:D000014', 'Disease') :: ['malformations', 'Types of malformations']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity2439 :: ('MESH:D014201', 'Disease') :: ['Trematode']

entities_list: @entity29877 :: ('30335', 'Species') :: ['D. melanostictus', 'Asian Common Toad', 'Duttaphrynus melanostictus']

answer: @entity29877 :: (30335,Species) :: ['Asian Common Toad']


abstract: OBJECTIVES: @entity713 ( @entity713 ) is a infrequent and serious complication after percutaneous @entity2438 closure. In this study, we report on the incidence of @entity713 associated with intraoperative device closure of the @entity2438 with transthoracic minimal invasion, and the outcomes of this complication in our center. METHODS: Between May 2006 and January 2011, a total of 213 secundum-type @entity2438 @entity1 were accepted in our hospital for intraoperative and transthoracic device closure with a domestic occluder. All @entity1 were assessed by @entity1054 ( @entity1054 ) and electrocardiograph (ECG). RESULTS: All @entity1 were occluded successfully under this approach. Immediate postprocedure third-degree @entity713 was observed in two @entity1 . Since heart rates were in the range of about 50 to 55 beats per minute, no intervention was needed except for close observation for one @entity1 . Another @entity1 who recovered sinus rhythm intermittently during the operation was fitted with a temporary pacemaker. Approximately one week following glucocorticoid treatment, the @entity713 resolved spontaneously in these two @entity1 . @entity713 occurred in three @entity1 during the procedure. Two @entity1 developed post-operative @entity1167 and were rescued successfully with cardiopulmonary resuscitation. One other @entity1 changed to Mobitz type I @entity713 after three days. During the follow-up period, which ranged from six months to five years, no further occurrence of @entity713 was found. CONCLUSIONS: Intraoperative and transthoracic device closure of secundum ASDs with domestic occluder resulted in excellent closure rate. @entity713 is an infrequent but serious complication during and after device closure of a secundum @entity2438 . @entity713 is a complication that warrants greater attention and long-term follow-up.

title: XXXX subsequent to intraoperative device closure atrial septal defect with transthoracic minimal invasion; a rare and serious complication.

entities_list: @entity713 :: ('MESH:D054537', 'Disease') :: ['Mobitz type II AVB', 'Atrioventricular block', 'AVB']

entities_list: @entity1167 :: ('MESH:D006323', 'Disease') :: ['cardiac arrest']

entities_list: @entity1054 :: ('MESH:D000377', 'Disease') :: ['TTE', 'real-time transthoracic echocardiography']

answer: @entity713 :: (MESH:D054537,Disease) :: ['Atrioventricular block']


abstract: OBJECTIVE: The combination of @entity1499 (1 g/m(2) day 1), @entity1732 (10 mg day 3), and @entity2879 (100 mg/m(2) days 1-5) (MBE) has been used for disease relapse or as a second-line chemotherapy in the treatment of @entity1469 ( @entity1469 ) resistant to multiple-agent chemotherapy. With the identification of ultra-high-risk @entity1469 , MBE has also been used as first-line chemotherapy. The current study is to review the use of MBE in the treatment of @entity1469 . METHODS: @entity1 who received MBE for @entity1469 between 1985 and 2003 in Queen Mary Hospital were included in this study. Records were reviewed and data were analyzed. Outcomes including response rate, treatment complications, and survival were assessed. RESULTS: @entity1499 , @entity1732 , and @entity2879 therapy was given as first line to 4 @entity1 with ultra-high-risk @entity1469 . Three responded to the treatment and remained disease free. @entity1499 , @entity1732 , and @entity2879 were given as a second-line therapy to 8 @entity1 who had drug resistance to the initial therapy. Seven responded, and 6 remained disease free at 5 years. @entity1499 , @entity1732 , and @entity2879 were given as a second-line therapy to 8 @entity1 who relapsed 2-18 months after their initial therapy. Seven @entity1 responded, and 4 remained disease-free at 5 years, 2 defaulted, and one died of @entity694 . Of the 20 @entity1 who received MBE, 12 developed grade 3/4 @entity1398 , and 4 developed grade 3/4 @entity882 . The overall response rate for MBE was 85%. CONCLUSION: @entity1499 , @entity1732 , and @entity2879 should be considered as a second-line therapy in @entity1 who have drug-resistant or recurrent @entity1469 .

title: @entity1499 , @entity1732 , and @entity2879 in the treatment of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia']

entities_list: @entity1469 :: ('MESH:D031901', 'Disease') :: ['gestational trophoblastic neoplasia', 'GTN']

entities_list: @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia']

entities_list: @entity1732 :: ('MESH:D001761', 'Chemical') :: ['bleomycin']

entities_list: @entity1499 :: ('MESH:D008727', 'Chemical') :: ['Methotrexate', 'methotrexate']

entities_list: @entity694 :: ('MESH:D003110', 'Disease') :: ['carcinoma of the colon']

answer: @entity1469 :: (MESH:D031901,Disease) :: ['gestational trophoblastic neoplasia']


abstract: BACKGROUND: Tissue synchronizing imaging (TSI) allows visual detection of asynchronous @entity296 . Although it is a screening tool for the detection of left ventricular (LV) dyssynchrony, its use as a qualitative method to assess dyssynchrony has not been studied. We evaluated the correlation of the visual assessment of dyssynchrony using TSI with quantitative assessment, the value of visual assessment to predict reverse remodeling to cardiac resynchronization therapy (CRT). METHODS: Echocardiograms from 100 consecutive @entity1 were retrospectively evaluated. We compared visual TSI assessment with the qualitative assessment of dyssynchrony obtained by tissue Doppler imaging (TDI). The utility of visual assessment as a predictor of response to CRT was evaluated in 43 @entity1 . RESULTS: In 86% of the cases, visual assessment was possible, and reproducibility was unrelated to observer experience. Each grade of @entity227 corresponded to a range of values of time to peak velocity (TPV) gradient (p < 0.001). Grade >or=1 dyssynchrony by visual assessment had 90% sensitivity and 95% specificity to identify >or=65 ms TPV gradient of LV opposing walls, and 93% sensitivity and 70% specificity to predict reverse LV remodeling. CONCLUSION: @entity1002 may be visually assessed by TSI, which can also predict reverse LV remodeling.

title: Visual assessment of XXXX using tissue synchronization imaging.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity227 :: ('MESH:D014786', 'Disease') :: ['visual dyssynchrony']

entities_list: @entity296 :: ('MESH:D009202', 'Disease') :: ['myocardial contraction']

entities_list: @entity1002 :: ('MESH:D018487', 'Disease') :: ['LV dyssynchrony']

answer: @entity1002 :: (MESH:D018487,Disease) :: ['left ventricular dyssynchrony']


abstract: BACKGROUND: In @entity1 with completely resected @entity1149 , recurrence-free survival, postrecurrence survival, and metachronous @entity2 have not been well studied at the same time. METHODS: A total of 315 @entity1 with @entity1149 who underwent complete resection between 2001 and 2005 were examined. @entity1 were routinely assessed with computed tomography of the chest and physical checkups every 4 months for the first 2 years and every 6 months from the third to the fifth year. After that, they were examined annually. RESULTS: The overall 5-year survival was 70%. Of all 315 @entity1 , 107 had recurrent disease. The median recurrence-free survival was 15.7 months. Multivariate analysis showed that pathologic stage and @entity3 were associated with decreased recurrence-free survival. The median postrecurrence survival was 18.7 months. Multivariate analysis indicated that male sex, @entity3 , extrathoracic recurrence, and supportive care for recurrence were associated with decreased postrecurrence survival. The cumulative rate of metachronous @entity2 at 5 years was 3.7%, and it developed even 8 years after the initial operation. CONCLUSIONS: Only @entity3 of the @entity2 was related to both recurrence-free survival and postrecurrence survival. Moreover, postrecurrence survival was related to both site and treatment of the initial recurrence. The incidence of metachronous @entity2 was stable over time after the initial operation.

title: Results of long-term follow-up of @entity1 with completely resected XXXX .

entities_list: @entity1149 :: ('MESH:D002289', 'Disease') :: ['non-small cell lung cancer']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['pleural invasion']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['primary lung cancer', 'original lung cancer']

answer: @entity1149 :: (MESH:D002289,Disease) :: ['non-small cell lung cancer']


abstract: BACKGROUND: We present the results of @entity1 submitted to a Studer type urinary orthotopic derivation after radical cystectomy. METHODS: The files of @entity1 with @entity150 submitted to a radical cystectomy plus the procedure of the ileal neobladder were reviewed in our hospital from January 1992 until December 2004. @entity1 were divided into two groups: group A--60 years old or younger and group B-->60 years old. RESULTS: From 306 @entity1 submitted to radical cystectomy with urinary derivation, there were 42 @entity1 (13.7%) included with @entity164 . There were 34 (80.9 %) @entity1 and 8 (19.1%) @entity1 , with an average age of 60 years. Average surgical time was 7 h with an average @entity190 of 1600 cc requiring transfer to intensive care unit (ICU) in 55% of the cases. The most frequent @entity532 was @entity520 that was present in 28 (66%) @entity1 . The most severe complication was ileal-ureter urinary leak, which was present in seven (16.6 %) @entity1 . Among the most frequent late complications are the day- and night-time urinary incontinence often related to @entity293 and @entity432 . Overall 5-year survival was 71%, @entity5 -specific mortality was 15% and surgical-related mortality was 7.3%. CONCLUSIONS: The performance of procedures with orthotopic neobladders is actually feasible in experienced hospital centers and is a valuable alternative to urinary heterotopic derivation with ileal conduit. Postoperative @entity1 management and regular follow-up is of major importance.

title: Management of XXXX with Studer orthotopic neobladder: 13-year experience.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients', 'patient', 'men']

entities_list: @entity190 :: ('MESH:D006473', 'Disease') :: ['blood loss']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity532 :: ('MESH:D003925', 'Disease') :: ['early complication']

entities_list: @entity520 :: ('MESH:D000138', 'Disease') :: ['metabolic acidosis']

entities_list: @entity150 :: ('MESH:D001749', 'Disease') :: ['bladder cancer']

entities_list: @entity164 :: ('MESH:D017827', 'Disease') :: ['Studer type neobladder']

entities_list: @entity432 :: ('MESH:D001157', 'Disease') :: ['intestinal occlusion']

entities_list: @entity293 :: ('MESH:D014552', 'Disease') :: ['urinary infections']

answer: @entity150 :: (MESH:D001749,Disease) :: ['bladder cancer']


abstract: Clinical and preclinical studies on @entity71 ( @entity71 ) show that juvenile males that are exposed to @entity2727 ( @entity7541 ) show reduced risk for substance use later in life. In contrast, little is known about whether females have the same enduring treatment response to stimulants and how gonadal hormones influence their behavior later in life. Females received either a sham or @entity2955 ( @entity2955 ) microinjection in the prefrontal cortex (PFC) at postnatal day (P)10. Subjects were then treated with Vehicle or @entity7541 (2mg/kg, p.o.) between P20-35 and tested during late adolescence/young adulthood (P60); half of these subjects underwent ovariectomy at P55 to determine hormonal influences. Females with @entity2955 were depleted of PFC @entity935 by 61% and demonstrated increased impulsive choice (delayed discounting) and preferences for @entity2072 -associated environments relative to control females. Both @entity7541 and ovariectomy reduced impulsive choice and @entity2072 preferences in @entity2955 females, but had no enduring effect in Sham females. Ovariectomy itself did not significantly affect impulsivity. Juvenile @entity7541 interacted strongly with @entity2955 to increase D4, D5, Alpha-1A, Alpha-2A, and @entity750 -1A mRNA receptor expression in the PFC. @entity7541 alone effected D1 mRNA, while @entity2955 increased @entity2136 ; all markers were decreased by ovariectomy. Together, these data suggest that @entity2955 changes in @entity935 are not only relevant for @entity71 -like behaviors, but their long-term modulation by treatment and the influence of cyclical differences in menstrual cycle.

title: Preventative treatment in an animal model of XXXX : Behavioral and biochemical effects of @entity2727 and its interactions with ovarian hormones in female rats.

entities_list: @entity935 :: ('MESH:D004298', 'Chemical') :: ['dopamine']

entities_list: @entity71 :: ('MESH:D001289', 'Disease') :: ['ADHD', 'attention deficit hyperactivity disorder']

entities_list: @entity2955 :: ('MESH:D016627', 'Chemical') :: ['6-hydroxydopamine', '6-OHDA']

entities_list: @entity2727 :: ('MESH:D008774', 'Chemical') :: ['methylphenidate']

answer: @entity71 :: (MESH:D001289,Disease) :: ['ADHD']


abstract: The mechanical and energetic consequences of long-term pressure-overload (POL) @entity1184 have been investigated in @entity95 and compared with sham-operated controls (SOC). @entity1184 was induced by banding the pulmonary artery of young @entity95 and examining the mechanical, biochemical, and energetic properties of the compensated heart 10-16 wk later. Experiments were undertaken on papillary muscles from the @entity1184 hearts. At 27 degrees C and a stimulus frequency of 1 Hz there was a modest @entity308 of peak stress development but no significant changes in isometric rise times and one-half widths or in isotonic maximum velocity of shortening and power output. The inverse relationship between peak stress and cross-sectional area (CSA) was practically identical in the POL and SOC groups. Both polarographic and myothermic investigations were made on papillary muscles. @entity1184 nearly halved basal metabolism, and in isometric contractions there was increased isometric economy due to a combination of a lower stress cost and a reduced activation heat. @entity1184 did significantly depress the extent of shortening leading to a @entity998 per beat. In isotonic contractions the @entity998 was offset by a reduced energy output such that there was no significant change in suprabasal mechanical efficiency. Biochemical studies showed that the transition of myosin isoenzymes to the V3 form was essentially complete in the POL group, but that the SOC group was also predominantly V3 when the animals were killed. There was a significant 30% decline in the @entity141 -stimulated adenosinetriphosphatase activity of the sarcoplasmic reticulum. It is concluded that in long-term compensated @entity1184 of @entity95 hearts there are only a few mechanical and energetic differences between control and @entity1184 muscles. The changes that can be detected appear to predominantly reflect disturbances in cellular @entity141 regulation.

title: Mechanical, energetic, and biochemical changes in long-term pressure overload of XXXX heart.

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

entities_list: @entity998 :: ('MESH:D002303', 'Disease') :: ['reduced work output']

entities_list: @entity1184 :: ('MESH:D006984', 'Disease') :: ['hypertrophy', 'Hypertrophy', 'hypertrophic']

entities_list: @entity95 :: ('9986', 'Species') :: ['rabbits', 'rabbit']

answer: @entity95 :: (9986,Species) :: ['rabbit']


abstract: BACKGROUND: Much of the unskilled and semi-skilled workforce in Thailand comprises migrant workers from neighbouring countries. While, in principle, healthcare facilities in the host country are open to those migrants registered with the Ministry of Labour, their actual healthcare-seeking preferences and practices, as well as those of unregistered migrants, are not well documented. This study aimed to describe the patterns of healthcare-seeking behaviours of immigrant workers in Thailand, emphasizing healthcare practices for @entity1906 -suspicious symptoms, and to identify the role of occupation and other factors influencing these behaviours. METHODS: A survey was conducted among 614 immigrant @entity12767 ( @entity12767 ), @entity2144 ( @entity2144 ) and construction workers (CW), in which information was sought on socio-demography, history of illness and related healthcare-seeking behaviour. Mixed effects logistic regression modeling was employed in data analysis. RESULTS: Among all three occupations, self-medication was the most common way of dealing with illnesses, including the development of @entity1906 -suspicious symptoms, for which inappropriate drugs were used. Only for GI symptoms and obstetric problems did migrant workers commonly seek healthcare at modern healthcare facilities. For @entity221 , @entity12767 preferred to attend the in-factory clinic and @entity2144 a private facility over government facilities owing to the quicker service and greater convenience. For @entity2144 , who were generally wealthier, the higher cost of private treatment was not a deterrent. CW preferentially chose a government healthcare facility for their GI problems. For obstetric problems, including delivery, government facilities were utilized by @entity2144 and CW, but most @entity12767 returned to their home country. After adjusting for confounding, having legal status in the country was associated with overall greater use of government facilities and being female and being married with use of both types of modern healthcare facility. One-year estimated period prevalence of @entity1906 -suspicious symptoms was around 6% among @entity12767 but around 27% and 30% in @entity2144 and CW respectively. However, CW were the least likely to visit a modern healthcare facility for these symptoms. CONCLUSIONS: Self medication is the predominant mode of healthcare seeking among these migrant workers. When accessing a modern healthcare facility the choice is influenced by occupation and its attendant lifestyle and socioeconomic conditions. Utilization of modern facilities could be improved by reducing the current barriers by more complete registration coverage and better provision of healthcare information, in which local vendors of the same ethnicity could play a useful role. Active surveillance for @entity1906 among migrant workers, especially CW, may lead to better @entity1906 control.

title: Migrant workers' occupation and healthcare-seeking preferences for XXXX -suspicious symptoms and other health problems: a survey among immigrant workers in Songkhla province, southern Thailand.

entities_list: @entity12767 :: ('MESH:D000382', 'Disease') :: ['FW', 'factory workers']

entities_list: @entity221 :: ('MESH:D005334', 'Disease') :: ['GI illness']

entities_list: @entity2144 :: ('MESH:D020315', 'Disease') :: ['RT', 'rubber tappers']

answer: @entity1906 :: (MESH:D014390,Disease) :: ['TB']


abstract: OBJECTIVE: Treatment decisional preferences impact @entity0 @entity1 ' @entity283 ( @entity283 ) and may relate to psychological variables, although many aspects of this relationship remain unknown. This prospective study aimed to assess psychological correlates of treatment decisional preferences and predictors of @entity283 in @entity1 with early non-metastatic @entity0 . METHODS: Of the 124 @entity1 initially assessed for @entity148 (Spielberger's State-Trait @entity148 Inventory) and @entity308 (Center for Epidemiologic Studies-Depression (CES-D)) symptoms, @entity283 (WHOQOL-BREF), and defense mechanisms (Life Style Index), 82 (66.1%) completed the 1-year follow-up. Mean age was 54.6 years (SD = 9.76), and mean disease duration was 19.4 months (SD = 25.55); 19.5% had stage I, 63.4% stage II and 17.1% stage III disease. The predictive power and moderator effects of psychological variables were tested using multiple and @entity2357 models. RESULTS: @entity308 and physical @entity283 improved significantly, state @entity148 and mental and environment @entity283 remained stable, and social relations @entity283 deteriorated over the 1-year period. Older age (p = 0.021) and higher scores in repression defense (p = 0.044) were independently associated with passive decisional preferences. Earlier stage of @entity5 (p = 0.043), lower state @entity148 (p = 0.039), lower repression scores (p = 0.021) and improvement in @entity308 (p < 0.001) predicted physical @entity283 improvement. Moderation analysis showed that active decisional preferences predicted physical @entity283 improvement, but only in those @entity1 with lower repression levels. CONCLUSIONS: Defense mechanisms are associated with treatment decisional preferences and interact with factors predicting @entity283 in @entity1 with @entity0 . Clinicians should address the @entity1 ' @entity148 and @entity308 and refer @entity1 with high repression tendencies for psychological evaluation and management.

title: XXXX , @entity308 and defense mechanisms associated with treatment decisional preferences and quality of life in non-metastatic @entity0 : a 1-year prospective study.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depressive symptoms', 'depressive', 'Depressive symptoms']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity283 :: ('OMIM:603663', 'Disease') :: ['HRQoL', 'health-related quality of life']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity2357 :: ('MESH:C537770', 'Disease') :: ['hierarchical regression']

entities_list: @entity148 :: ('MESH:D001008', 'Disease') :: ['Anxiety', 'anxiety']

answer: @entity148 :: (MESH:D001008,Disease) :: ['Anxiety']


abstract: The quantities of @entity1815 and @entity53 were determined by radioimmunoassay in maternal and fetal plasma of the @entity2608 from day 59 to 163 of gestation. A two way analysis of variance of data classified according to fetal sex and 3 pooled gestational ages for each hormone and for mother or fetus (4 analyses) revealed significant elevations in fetal @entity53 and maternal @entity1815 concentrations with age. All other comparisons were not significant by these analyses. The concentrations of @entity53 were greater in maternal than in fetal plasma [769 +/- 64 (SE) pg/ml, N = 63 VS 57 +/- 6 (SE) pg/ml, N = 77, P less than 0.01] by a t test. @entity1815 , on the other hand, was similar in mother and fetus [265 +/- 30 (SE) pg/ml, N = 60 vs 318 +/- 37 (SE) pg/ml, N = 73, P greater than 0.05]. No sex differences in the concentrations of these hormones were observed except in the fetus after 150 days of gestation. At this time plasma from female fetuses contained significantly more @entity53 than plasma from male fetuses [118 +/- 20 (SE) pg/ml, N = 7 vs 61 +/- 10 (SE) pg/ml, N = 19, P less than 0.01]. Except for @entity53 in female fetuses, the concentrations of @entity172 were significantly higher in the umbilical vein than in the umbilical artery, an indication that the placenta is a major source of fetal @entity172 in this species. @entity1815 and @entity53 were significantly correlated in both the fetal and maternal circulation, r = 0.58, P less than 0.001 and r = 0.39, P less than 0.01 respectively. The results provide quantitative data about the @entity172 miliue in which the monkey fetus develops and suggest mechanisms for controlling fetal @entity172 in this species.

title: Estrogens in fetal and maternal plasma of the XXXX ,.

entities_list: @entity2608 :: ('9544', 'Species') :: ['rhesus monkey']

entities_list: @entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen']

entities_list: @entity53 :: ('MESH:D004958', 'Chemical') :: ['estradiol']

entities_list: @entity1815 :: ('MESH:D004970', 'Chemical') :: ['Estrone', 'estrone']

answer: @entity2608 :: (9544,Species) :: ['rhesus monkey']


abstract: Intracellular @entity460 ([ @entity141 ](i)) is the most relevant modulator of parathyroid hormone ( @entity461 ) secretion. Uniquely, an increase in [ @entity141 ](i) results in an inhibition of @entity461 secretion, and it probably exerts its function via @entity460 -binding protein pathways. The ubiquitous @entity460 -binding proteins, calmodulin and @entity3404 ( @entity3404 ), have well-established roles in regulated exocytosis in neurons and neuroendocrine cells. However, their roles in parathyroid cells and @entity461 secretion are still unclear. Using reverse transcription-PCR and western blot analysis, we have demonstrated the expression of calmodulin and @entity3404 in @entity1 normal parathyroid and parathyroid chief cell @entity652 . Blocking of calmodulin and @entity3404 activity by the specific antagonists calmidazolium and @entity10756 respectively caused a rise in @entity461 secretion from @entity3243 cells in spite of increased [ @entity141 ](i). The inhibitory effect of @entity141 calmodulin on @entity461 secretion may be due to the absence of @entity22880 protein in @entity3243 , as demonstrated by western blot analysis. An increased extracellular @entity460 level acutely lowered the amount of active phosphorylated @entity3404 (pCaMKII) in @entity652 cells in vitro, indicating the physiological importance of this pathway. Moreover, a negative correlation between the levels of pCaMKII in @entity3243 and serum @entity460 was found in 20 @entity1 with @entity459 . Taken together, these results show that calmodulin negatively contributes to the regulation of @entity461 secretion in @entity3243 , at least partially via a @entity3404 pathway.

title: Calmodulin and @entity3404 inhibit hormone secretion in XXXX @entity3243 .

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity459 :: ('MESH:D049950', 'Disease') :: ['primary hyperparathyroidism']

entities_list: @entity3404 :: ('818', 'Gene') :: ['CaMKII', 'calmodulin-dependent protein kinase II']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

entities_list: @entity3243 :: ('MESH:D010282', 'Disease') :: ['parathyroid adenoma', 'parathyroid adenomas']

entities_list: @entity652 :: ('MESH:D000236', 'Disease') :: ['adenomas', 'adenoma']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: @entity3384 with or without @entity2419 ( @entity2419 ) is one of the most common @entity600 worldwide and is characterized by abnormalities of the orofacial structure. Syndromic @entity2419 is mainly caused by @entity74 such as @entity558 ( @entity558 ). However, >70% of @entity2419 cases are nonsyndromic, characterized by isolated @entity13797 without any known syndrome. The etiology of nonsyndromic @entity2419 ( @entity9147 /P) remains elusive, but it has been suggested that causative genes of @entity2419 might also contribute to @entity9147 /P. As such, the @entity558 causative gene @entity23970 has been extensively studied in @entity9147 /P. Recently, @entity33896 was identified as another @entity558 causative gene. Thus, it may be a novel candidate gene for @entity9147 /P. In the present study, we genotyped 10 tag SNPs covering @entity33896 and performed association analysis with @entity9147 /P in 504 cases and 455 healthy controls. Our preliminary results identified @entity33897 , @entity33898 , and a haplotype @entity33897 - @entity33899 of @entity33896 that exceeded the significance threshold (p<0.05), though none survived Bonferroni correction for multiple comparisons. As the first study between @entity33896 and @entity9147 /P, the contribution of this gene to @entity9147 /P etiology should be interpreted with caution based on existing evidence. Further, the robustness of association between @entity33896 and @entity9147 /P should be further validated in expanded cohorts.

title: Association study between @entity558 causative gene XXXX and @entity3384 with or without @entity2419 in a Chinese cohort.

entities_list: @entity13797 :: ('MESH:C566121', 'Disease') :: ['orofacial cleft']

entities_list: @entity558 :: ('MESH:C536528', 'Disease') :: ['Van der Woude Syndrome', 'VWS']

entities_list: @entity600 :: ('MESH:D000014', 'Disease') :: ['birth defects']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['Mendelian disorders']

entities_list: @entity2419 :: ('MESH:D002972', 'Disease') :: ['CL/P', 'cleft palate', 'syndromic CL/P']

answer: @entity33896 :: (57822,Gene) :: ['GRHL3']


abstract: OBJECTIVE: Sporadic, genetically complex essential @entity400 (ET) is one of the most common @entity717 and may lead to severe impairment of the quality of life. Despite high heritability, the genetic determinants of ET are largely unknown. We performed the second genome-wide association study (GWAS) for ET to elucidate genetic risk factors of ET. METHODS: Using the Affymetrix Genome-Wide SNP Array 6.0 (1000K) we conducted a two-stage GWAS in a total of 990 subjects and 1,537 control subjects from Europe to identify genetic variants associated with ET. RESULTS: We discovered association of an intronic variant of the main glial @entity2227 transporter ( @entity9320 ) gene with ET in the first-stage sample ( @entity33903 , p = 6.95   10(-5), odds ratio [OR] = 1.46). We verified the association of @entity33903 with ET in a second-stage sample (p = 1.25   10(-3), OR = 1.38). In the subgroup analysis of @entity1 classified as definite ET, @entity33903 obtained genome-wide significance (p = 3.44   10(-10), OR = 1.59) in the combined first- and second-stage sample. Genetic fine mapping using nonsynonymous single nucleotide polymorphisms (SNPs) and SNPs in high linkage disequilibrium with @entity33903 did not reveal any SNP with a stronger association with ET than @entity33903 . CONCLUSIONS: We identified @entity9320 encoding the major glial high-affinity @entity2227 reuptake transporter in the brain as a potential ET susceptibility gene. Acute and chronic glutamatergic overexcitation is implied in the pathogenesis of ET. @entity9320 is therefore a good functional candidate gene for ET.

title: Polymorphisms in the glial XXXX transporter @entity9320 are associated with essential @entity400 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity2227 :: ('CHEBI:29987', 'Chemical') :: ['glutamate']

entities_list: @entity717 :: ('MESH:D009069', 'Disease') :: ['movement disorders']

answer: @entity2227 :: (CHEBI:29987,Chemical) :: ['glutamate']


abstract: A 72-year-old @entity1 had a @entity1653 that invaded through the skull and into temporalis muscle. One year following craniotomy for @entity5 , he developed @entity10 , @entity892 , and @entity735 . Biopsy of the orbital contents revealed a malignant supporting tissue @entity5 having a resemblance to the previous @entity1653 . No curative therapy was possible and the @entity1 died 33 months after diagnosis. Autopsy examination showed extensive @entity1313 and a 3-cm metastasis in the liver. The @entity3 appeared similar to the @entity1653 and did not appear malignant histologically. The case illustrates the distinct histologic variations in @entity1653 and the difficulties in predicting their biologic activity. Aggressive local behavior may indicate possible malignant areas in the @entity5 . Therefore, examination of the @entity5 should be thorough. Such a correlation may suggest malignant biologic potential.

title: XXXX with sarcomatous change and hepatic metastasis.

entities_list: @entity1313 :: ('MESH:D001932', 'Disease') :: ['residual intracranial neoplasm']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['removal of the neoplasm', 'neoplasm']

entities_list: @entity735 :: ('MESH:D005124', 'Disease') :: ['proptosis of the left eye']

entities_list: @entity1653 :: ('MESH:D008579', 'Disease') :: ['meningiomas', 'meningotheliomatous meningioma', 'meningioma']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastatic tumor']

entities_list: @entity892 :: ('MESH:D004172', 'Disease') :: ['diplopia']

entities_list: @entity10 :: ('MESH:D006261', 'Disease') :: ['headaches']

answer: @entity1653 :: (MESH:D008579,Disease) :: ['Meningioma']